ATE506073T1 - Verfahren zur modulation der angiogenese mittels der tyrosin kinase src - Google Patents

Verfahren zur modulation der angiogenese mittels der tyrosin kinase src

Info

Publication number
ATE506073T1
ATE506073T1 AT99924535T AT99924535T ATE506073T1 AT E506073 T1 ATE506073 T1 AT E506073T1 AT 99924535 T AT99924535 T AT 99924535T AT 99924535 T AT99924535 T AT 99924535T AT E506073 T1 ATE506073 T1 AT E506073T1
Authority
AT
Austria
Prior art keywords
src protein
nucleic acids
acids encoding
angiogenesis
tyrosine kinase
Prior art date
Application number
AT99924535T
Other languages
English (en)
Inventor
David Cheresh
Brian Eliceiri
Pamela L Schwartzberg
Original Assignee
Scripps Research Inst
Us Government
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Us Government filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE506073T1 publication Critical patent/ATE506073T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
AT99924535T 1998-05-29 1999-05-28 Verfahren zur modulation der angiogenese mittels der tyrosin kinase src ATE506073T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8722098P 1998-05-29 1998-05-29
PCT/US1999/011780 WO1999061590A1 (en) 1998-05-29 1999-05-28 Methods and compositions useful for modulation of angiogenesis using tyrosine kinase src

Publications (1)

Publication Number Publication Date
ATE506073T1 true ATE506073T1 (de) 2011-05-15

Family

ID=22203825

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99924535T ATE506073T1 (de) 1998-05-29 1999-05-28 Verfahren zur modulation der angiogenese mittels der tyrosin kinase src

Country Status (23)

Country Link
US (1) US7585841B2 (de)
EP (1) EP1082415B1 (de)
JP (1) JP4806487B2 (de)
KR (1) KR20010085261A (de)
CN (1) CN1304567C (de)
AT (1) ATE506073T1 (de)
AU (1) AU762955C (de)
BR (1) BR9910787A (de)
CA (1) CA2330025C (de)
CZ (1) CZ302918B6 (de)
DE (1) DE69943374D1 (de)
DK (1) DK1082415T3 (de)
ES (1) ES2361659T3 (de)
HU (1) HU227985B1 (de)
MX (1) MXPA00011821A (de)
NO (1) NO327610B1 (de)
PT (1) PT1082415E (de)
RU (1) RU2222342C2 (de)
SK (1) SK287330B6 (de)
TR (1) TR200100430T2 (de)
UA (1) UA75565C2 (de)
WO (1) WO1999061590A1 (de)
ZA (1) ZA200007321B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA00011821A (es) * 1998-05-29 2004-07-30 Scripps Research Inst Metodos y composiciones utiles para la modulacion de la angiogenesis usando tirosina-cinasa src.
US20030130209A1 (en) * 1999-12-22 2003-07-10 Cheresh David A. Method of treatment of myocardial infarction
US6685938B1 (en) * 1998-05-29 2004-02-03 The Scripps Research Institute Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
EP1250155B1 (de) * 1999-12-22 2008-04-16 The Scripps Research Institute Modulatoren und inhibitoren von angiogenese und vaskulärer durchlässigkeit
US7485414B2 (en) 2002-08-30 2009-02-03 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
WO2008054792A2 (en) * 2006-10-31 2008-05-08 University Of Toledo Na+/k+-atpase-specific peptide inhibitors/activators of src and src family kinases
DE102007037008B4 (de) * 2007-08-06 2015-09-10 Siemens Aktiengesellschaft Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors
WO2010105172A1 (en) 2009-03-13 2010-09-16 Abraxis Bioscience, Llc Combination therapy with thiocolchicine derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7432496A (en) * 1995-10-13 1998-05-11 Regents Of The University Of Minnesota Consolidated ligands with increased affinities and methods of use thereof
US6335010B1 (en) * 1996-11-08 2002-01-01 University Of California At San Diego Gene therapy in coronary angioplasty and bypass
MXPA00011821A (es) * 1998-05-29 2004-07-30 Scripps Research Inst Metodos y composiciones utiles para la modulacion de la angiogenesis usando tirosina-cinasa src.
GB2341182A (en) * 1998-09-01 2000-03-08 Yamanouchi Uk Ltd Protein comprising amino acid sequences having SH3 domain binding activity and nuclear localisation activity

Also Published As

Publication number Publication date
CA2330025A1 (en) 1999-12-02
CA2330025C (en) 2009-03-17
EP1082415A4 (de) 2003-07-09
ZA200007321B (en) 2002-03-08
SK18112000A3 (sk) 2001-09-11
EP1082415A1 (de) 2001-03-14
AU762955C (en) 2005-03-24
NO327610B1 (no) 2009-08-31
HK1041289A1 (en) 2002-07-05
SK287330B6 (sk) 2010-07-07
WO1999061590A1 (en) 1999-12-02
US7585841B2 (en) 2009-09-08
US20060009412A1 (en) 2006-01-12
HUP0102614A2 (hu) 2001-11-28
JP4806487B2 (ja) 2011-11-02
PT1082415E (pt) 2011-07-04
DK1082415T3 (da) 2011-06-14
MXPA00011821A (es) 2004-07-30
WO1999061590A9 (en) 2000-03-09
CZ302918B6 (cs) 2012-01-18
ES2361659T3 (es) 2011-06-21
KR20010085261A (ko) 2001-09-07
BR9910787A (pt) 2001-10-30
HU227985B1 (en) 2012-07-30
NO20006026L (no) 2001-01-24
UA75565C2 (uk) 2006-05-15
CN1304567C (zh) 2007-03-14
JP2002516344A (ja) 2002-06-04
RU2222342C2 (ru) 2004-01-27
TR200100430T2 (tr) 2002-05-21
AU4101399A (en) 1999-12-13
EP1082415B1 (de) 2011-04-20
CZ20004435A3 (en) 2001-06-13
NO20006026D0 (no) 2000-11-28
HUP0102614A3 (en) 2005-11-28
DE69943374D1 (de) 2011-06-01
AU762955B2 (en) 2003-07-10
CN1319131A (zh) 2001-10-24

Similar Documents

Publication Publication Date Title
WO2003089457A3 (en) Peptide inhibitors of protein kinase c ϝ for pain management
ATE269295T1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
ATE494388T1 (de) Neues verfahren zum erschaffen von proteinkinase- inhibitoren
ATE286053T1 (de) Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
ATE454161T1 (de) Verwendung von fviia oder fviiai zur behandlung von endothelialer fehlfunktion bzw zur inhibierung der angiogenese
ATE287402T1 (de) Nanomolare, non-peptidische inhibitoren von cathepsin d
ATE506073T1 (de) Verfahren zur modulation der angiogenese mittels der tyrosin kinase src
ATE471722T1 (de) Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen
DK1905457T3 (da) Farmaceutiske sammensætninger omfattende Src og/eller Yes samt anvendelse deraf
DE60139544D1 (de) Veränderte, fluoreszierende proteine
WO2002046384A3 (en) Kinases and phosphatases sequences, and use thereof
DE60136607D1 (de) System und Verfahren zur Lieferung von Karteninformationen
AU2001289034A1 (en) Novel pdes and uses thereof
ATE384740T1 (de) Nukleinsäuren, polypeptide und verfahren zur modulierung der apoptose
DE60137721D1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
WO1999038981A3 (en) Human protein kinase molecules
ATE489466T1 (de) Nukleinsäuren zur hemmung der expression von hairless-protein und verfahren zur verwendung davon
ATE498014T1 (de) Identifizierung und funktionelle charakterisierung einer ribosomalen s6 proteinkinase
DE60128950D1 (de) Proteine aus yaba monkey tumor virus mit modulatorischer aktivität
SE0302965D0 (sv) Hämmare av DNA-Metyltransferasisoformer
DE60333747D1 (de) Dna-enzym zur hemmung von plasminogenaktivator-inhibitor-1
SE9803958D0 (sv) Method for screening
WO2003012102A3 (fr) Acides nucleiques codant des proteines a domaine hect
SE0002364D0 (sv) Growth Factors
WO2003049691A3 (en) Antisense modulation of pctaire protein kinase 1 expression

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1082415

Country of ref document: EP